🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  3. elafibranor, Elafibranor Placebo

    Ipsen

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  4. elafibranor, Placebo

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  5. elafibranor, Placebo tablet

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  6. elritercept, Placebo to match ker-050 solution for injection

    Takeda

    myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  7. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib

    AB Science

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  9. masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib

    AB Science

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  10. matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  11. placebo

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  12. placebo

    Takeda

    Non-cancer Pain

    phase 3 small molecule terminated

    1 trial

  13. placebo

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  14. placebo

    Boehringer Ingelheim

    Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  15. placebo

    Pfizer

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  16. placebo (saline)

    Sanofi Pasteur

    Sphingomyelin Lipidosis

    phase 3 small molecule completed

    1 trial

  17. placebo for risankizumab

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  18. placebo for risankizumab IV

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  19. placebo ketamine inj prep, KETAMINE RENAUDIN 10 mg/ml, solution injectable

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

  20. placebo of metformine, METFORMINE VIATRIS 500 mg, comprimé dispersible

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  21. placebo plus docetaxel

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  22. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  23. riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Polyneuropathy, Inflammatory Demyelinating, Chronic

    phase 3 small molecule active

    1 trial

  24. riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources